for extracorporeal membrane oxygenation (ECMO) in ARDS has not been well defined (21) .
Objectives: Prior studies suggest hypothermia may be beneficial in acute respiratory distress syndrome, but cooling causes shivering and increases metabolism. The objective of this study was to assess the feasibility of performing a randomized clinical trial of hypothermia in patients with acute respiratory distress syndrome receiving treatment with neuromuscular blockade because they cannot shiver. Design: Retrospective study and pilot, prospective, open-label, feasibility study. Setting: Medical ICU. Patients: Retrospective review of 58 patients with acute respiratory distress syndrome based on Berlin criteria and Pao 2 /Fio 2 less than 150 who received neuromuscular blockade. Prospective hypothermia treatment in eight acute respiratory distress syndrome patients with Pao 2 /Fio 2 less than 150 receiving neuromuscular blockade. Intervention: Cooling to 34-36°C for 48 hours.
Measurements and Main Results:
Core temperature, hemodynamics, serum glucose and electrolytes, and P/F were sequentially measured, and medians (interquartile ranges) presented, 28-day ventilator-free days, and hospital mortality were calculated in historical controls and eight cooled patients. Average patient core temperature was 36.7°C (36-37.3°C), and fever occurred during neuromuscular blockade in 30 of 58 retrospective patients. In the prospectively cooled patients, core temperature reached target range less than or equal to 4 hours of initiating cooling, remained less than 36°C for 92% of the 48 hours cooling period without adverse events, and was lower than the controls (34.35°C .8°C]; p < 0.0001). Compared with historical controls, the cooled patients tended to have lower hospital mortality (75% vs 53.4%; p = 0.26), more ventilator-free days ( Conclusions: Neuromuscular blockade alone does not cause hypothermia but allowed acute respiratory distress syndrome patients to be effectively cooled. Results support conducting a randomized clinical trial of hypothermia in acute respiratory distress syndrome and the feasibility of studying acute respiratory distress syndrome patients receiving neuromuscular blockade. (Crit Care Med 2017; 45:1152-1159) Key Words: acute respiratory distress syndrome; neuromuscular blockade; therapeutic hypothermia T he acute respiratory distress syndrome (ARDS) remains an important health problem with substantial mortality (1, 2) and morbidity (3) (4) (5) (6) (7) (8) (9) . Despite advances in understanding of ARDS pathogenesis (10, 11) , only three interventions have been shown to reduce mortality in phase III randomized controlled trials (RCTs): low tidal volume ventilation (12) , neuromuscular blockade (NMB) (13) , and prone positioning (14) and mortality in moderate to severe ARDS remains greater than 40% (15, 16) . Other than NMB, pharmacologic therapies have been disappointing (17) (18) (19) (20) , and a role for extracorporeal membrane oxygenation (ECMO) in ARDS has not been well defined (21) .
Several studies suggest that clinically relevant hypothermia suppresses signaling pathways that contribute to pulmonary endothelial dysfunction, including mitogen-activated protein kinases and transient receptor vanilloid 4 (22-24) , and mitigates multiple animal models of acute lung injury (25) (26) (27) (28) (29) (30) (31) (32) . A small, nonrandomized concurrently controlled trial found hypothermia (33.7°C ± 0.6°C for 70 ± 15 hr) improved survival from 0/0 to 3/9 in moribund patients with septic shock and ARDS (33) . That study preceded the American-European Consensus Conference and Berlin definitions of ARDS and adoption of ARDS Network (ARDSNet) protocols for ventilation and fluid management, and mortality in both groups was much higher than current experience. A more recent retrospective review of postcardiac arrest hypothermia showed that standard hypothermia treatment (core temperature, 32-34°C) tended to be associated with improved pulmonary function (34) .
Although this evidence suggests that hypothermia would benefit ARDS patients, cooling in critically ill patients is complicated by shivering and its adverse metabolic consequences (35) . The recent addition of NMB to ARDS management protocols (36) provides an opportunity to avoid the problem of shivering in an initial study of hypothermia in ARDS, since treatment with NMB would prevent shivering. This pilot study was designed to assess the feasibility and direct the design of a potential RCT of targeted temperature management in ARDS patients receiving NMB. We retrospectively analyzed body temperatures in ARDS patients receiving NMB. We then performed a pilot study of mild hypothermia to 34-36°C for 48 hours in patients with ARDS receiving NMB to evaluate effectiveness and safety of cooling. Finally, we estimated effect size of hypothermia on potential outcome measures by comparing with historical controls.
MATERIALS AND METHODS

Retrospective Analysis
Potential patients were identified by searching the University of Maryland Medical Center (UMMC) pharmacy database for medical ICU (MICU) patients who received continuous cisatracurium infusions between 2012 and 2015. Charts and electronic records were analyzed for data to support diagnosis of moderate to severe ARDS based on Berlin criteria with Pao 2 / Fio 2 (P/F) ratio less than 150 based on simultaneous assessment of Fio 2 and Pao 2 with positive end-expiratory pressure (PEEP) greater than or equal to 5 cm H 2 O (37). The selected records were further reviewed for information about physiologic and clinical outcomes.
Prospective Cooling Pilot
The University of Maryland, Baltimore, Institutional Review Board approved the retrospective study, including waiver of consent and approval for a pilot prospective study of eight subjects. Between October 2015 and April 2016, we screened consecutive patients 18 years old or older admitted to the UMMC MICU or Critical Care Resuscitation Unit with a diagnosis of ARDS based on Berlin criteria with P/F ratio less than 150 measured with PEEP greater than or equal to 5 cm H 2 O (37) within 72 hours and who had started NMB within 24 hours of consent. Exclusion criteria were active bleeding, refractory hypotension, pregnancy, unlikely to remain intubated or alive 48 hours, skin lesions that interfere with cooling, and ECMO treatment during the hospitalization. After consent was obtained from the patient's legally authorized representative, a baseline blood sample was obtained and cooling was initiated using the UMMC therapeutic hypothermia protocol. A target temperature of 34-36°C was arbitrarily selected based on a recent study of cardiac arrest survivors (38) . Cooling was performed using the Arctic Sun system (Medivance, Inc., Louisville, CO) in two patients and Cincinnati Sub-Zero Blanketrol II (Cincinnati, OH) cooling blankets in six. Temperature was measured from esophageal (7) or urinary (1) probes. After 48 hours at target temperature, patients were rewarmed by 0.33°C/hr until core temperature reached 37°C and the cooling devices were removed. Patients received usual MICU care, including telemetry, protocolized ventilator management based on ARDSNet guidelines (12) , management of sedation and NMB using the UMMC institutional protocol, blood glucose monitoring, and daily laboratory measurements for electrolytes, serum creatinine, and complete blood counts. Blood for serum was collected at enrollment and study days 1, 2, 3, and 7 and analyzed for interleukin (IL)-6, IL-10, and total transforming growth factor (TGF)-β in the University of Maryland Cytokine Core Laboratory using reagents from R&D Systems (Minneapolis, MN).
Outcomes
To facilitate comparison between cooled patients and historical controls, we defined day 0 as beginning 06:00 on the day NMB began; cooling started some time on day 0 and ended some time on day 2. Demographic information, comorbidities, and disease severity measures were recorded at baseline. Core temperature, mean airway pressure, PEEP, and Fio 2 were recorded every 2 hours. The highest and lowest serum glucose, potassium, and magnesium levels were recorded, and 28-day ventilator-free days (VFDs), ICU-free days (ICU-FDs), and duration of NMB were calculated. All arterial blood gas values obtained on days 0-3 were entered into the database for calculation of P/F ratio and oxygenation index (OI), and the mean of the best and worst values for each day was used for analysis. Complications during the cooling period and subsequent ICU course were prospectively identified from discussions with the clinical team and examination of the medical records. Hypoglycemia and hyperglycemia were defined as serum glucose less than 70 and greater than 180, respectively. Electrolytes were considered abnormal if they fell out of the normal range for the UMMC clinical laboratory, 3.5-5.1 mmol/L for potassium and 1.6-2.5 mg/dL for magnesium.
Statistical Analysis
We summarized the temperature response in each control as mean of temperature measurements during NMB and in each prospectively cooled patient as mean of temperature measurements during cooling beginning with the first temperature less than 36°C. We compared the medians of the temperature responses in the two groups with a Wilcoxon rank-sum test. The distributions of temperature over time between 32°C and 39°C were compared visually by constructing histograms in half-degree increments for the two groups. Since the number of relevant temperature measurements differed among individuals, we compared the means of all temperature measurements in the two groups during NMB and cooling, respectively, using a mixed model repeated measures (MMRMs) analysis (39) with first-order autoregressive correlation and group as the only independent variable. Two primary sets of analyses were performed, one comparing cooled patients with all 58 controls and the other comparing cooled patients with a subset of matched controls. Two controls were matched to each cooled patients based on enrollment Acute Physiology and Chronic Health Evaluation (APACHE) II score and P/F ratio, underlying cause, age, body mass index, and gender, in that order by two of the authors (J.D.H., C.B.S.) who were blind to outcome. When controls were similar to cases except for pneumonia as the underlying cause, we accepted nonpneumonia sepsis as sufficiently similar. Statistical analysis was performed using the SAS version 9.3 statistical software package (SAS Institute, Cary, NC). Quantitative data are presented as median (interquartile range). Comparisons between cooled patients and all 58 controls were tested using the Wilcoxon-Mann-Whitney test for quantitative variables and Fisher exact test for dichotomous data. Comparisons between cooled patients and matched controls were tested using the Friedman test for quantitative data and the Cochran-Mantel-Haenszel chi-square test for matched dichotomous variables. Statistical significance was defined as a two-sided p value of less than 0.05.
RESULTS
Retrospective Analysis of Core Temperatures During NMB in ARDS Patients
Retrospective analysis of UMMC MICU patients between 2012 and 2015 identified 148 patients who received continuous infusion of cisatracurium, of whom 113 met criteria for moderate to severe ARDS (Fig. 1A) . Thirty-six patients were excluded because they did not survive 48 hours from start of NMB. Thirteen more were excluded because they received ECMO, one because of lung transplant, and five because their medical records were incomplete.
Fifty-eight patients with moderate to severe ARDS who received continuous infusion of cisatracurium were included in the retrospective study ( Table 1) . Thirty-two men and 26 women were 49 (38-57) years old. The group had high disease severity with APACHE II scores 23.5 (19.75-30) and severe oxygenation defect with P/F ratio 91 (75-110) and OI 24 (15.8-34.6 ). The underlying causes of ARDS were pneumonia (22) , nonpulmonary sepsis (30), nonseptic shock (1), blood product transfusion (4), and hemophagocytic lymphohistiocytosis (1). These patients had 0 (0-12) VFDs and 0 (0-6) ICU-FDs. ICU and hospital mortality were 51.7% and 53.5%, respectively. Duration of cisatracurium infusion was 57.5 (29.75-82) hours.
Core temperature was measured centrally from esophageal probes in 34 control patients or urinary catheter in one, rectally in 11, orally in three, axillary in seven, and unspecified in two. Core temperature was 36.9°C (36.2-37.8°C) at initiation of cisatracurium. The mean of temperature measurements during cisatracurium infusion was 36.6°C (36-37.3°C) (Fig.  1B) . Core temperature was less than 36°C for greater than or equal to 6 hours during NMB in 22 of the 58 controls, 17 of whom were receiving continuous renal replacement therapy (CRRT) (Fig. 1C) . Of those not receiving CRRT, only one had core temperature less than 35°C. Fever (> 38°C) occurred in 30 of 58 patients (52%) receiving cisatracurium, indicating that NMB alone was insufficient to block fever or induce hypothermia, but may have allowed hypothermia when combined with CRRT.
Effectiveness of Surface Cooling in ARDS Patients Treated With NMB
We performed an open-label pilot study of therapeutic hypothermia (core temperature, 34-36°C for 48 hr) in patients with ARDS and P/F less than 150 who were receiving cisatracurium ( Table 2) . Six men and two women were 55.5 (46-59) years old and were similar to the historical controls at precisatracurium baseline (Table 1) . At enrollment, median APACHE II score was 30 (24-32.75), P/F ratio was 86.5 (63-104), and OI was 19 (16.4-26.3). ARDS was caused by pneumonia in all eight subjects and was a complication of influenza infection in four. Core temperature at enrollment was 37°C (36.1-38.0°C). Patient number 8 was receiving CRRT and was already at target temperature at enrollment but required external cooling for part of the 48-hour treatment period.
Target temperature was reached by 11 (5.25-15.5) hours after initiation of cisatracurium and by 4 (2.25-9) hours after cooling device placement. Once target core temperature was achieved, it was maintained between 34°C and 36°C for 76% and between 33°C and 36°C for 92% of the cooling period. The median of the mean core temperatures during cooling for the eight subjects was lower than median of the mean core temperatures during NMB in the 58 controls ( (Fig. 1B) . The histograms, conveying the distribution of all core temperature measurements in the two groups, show a partial overlap (Fig. 1C) . The overall mean of the distribution for the cooled group (34.4°C) was lower than the mean of the distribution in the control group (36.7°C) in the MMRM analysis (p < 0.0001). Core temperature was greater than 36°C for 78% of the NMB infusion time for the historical controls compared with 2.5% of the cooling period for the prospectively cooled patients. We did not attempt to suppress fever after completion of the 48-hour cooling period. Two patients had fever in the 24 hours following cooling (Table S1, Supplemental Digital Content 1, http:// links.lww.com/CCM/C430). The average temperatures during NMB in the controls with and without CRRT were 36.2°C and 37.2°C, respectively.
Safety of Hypothermia in ARDS Patients Treated
With NMB All patients tolerated hypothermia without serious adverse events (SAEs). Two patients in the cooling group died following cooling ( Table 2) . Patient number 5, a 60-year-old man with hypertension and diabetes mellitus, presented with pneumonia, septic shock, and the poorest oxygenation in the cooling group. After completing the cooling protocol, he had fatal asystolic arrest during prone to supine positioning. The other death occurred in patient number 6, who had ARDS as a complication of newly diagnosed acute myelocytic leukemia, had improvement in OI from 20.7 to 7.3 by day 3, but died on study day 14 from septic shock.
The cooled patients and historical controls had similar frequencies of significant bleeding that was treated with at least two units of blood products (1/8 vs 8/58), symptomatic bradycardia (0/8 vs 1/58) during the cooling/ NMB period, and ventialtorassociated pneumonia (1/8 vs 7/58) ( Table 3) . Abnormalities in serum glucose, potassium, and magnesium were similar between the groups. Hypokalemia occurred in five patients during cooling and only one the day after cooling ended. One cooled patient, 13 of 58 controls, and five of 16 matched controls received CRRT prior to starting cisatracurium. Of the patients not already on CRRT at the start of cisatracurium infusion, cooled patients tended to receive renal replacement therapy more frequently during the cooling period than the 58 controls (4/7 vs 14/45; p = 0.21).
Comparing Physiologic and Clinical Outcomes With Historical Controls
Because the cooled patients tended to have higher APACHE II scores (30.0 vs 23.5; p = 0.15) and lower P/F ratios (86.5 vs 91.0; p = 0.4) at enrollment and higher frequency of pneumonia as underlying cause of ARDS (100% vs 38%), we compared cooled patients with all 58 controls and with 16 matched controls ( Table 4) . ICU and hospital mortality were both 25% in the cooled group, 68.8% and 75%, respectively, in the 16 matched controls (p = 0.061 and 0.027), and 51.7% and 53.4% in all 58 controls (p = 0.26 and 0.26). The distribution of VFDs was bimodal in the cooled patients; four patients had 0 VFDs and four had 18-22 VFDs. Two of the four with 0 VFDs died without liberating from the ventilator, and two others, who had preexisting cardiomyopathy and left ventricular ejection fraction less than 30%, required mechanical ventilation for 29 and 43 days. (Fig. S1 , B and C, Supplemental Digital Content 2, http://links.lww.com/CCM/ C431; legend, Supplemental Digital Content 3, http://links. lww.com/CCM/C432). One cooled patient and eight of 58 controls, but none of the matched controls, died before study day 3 and were not included in the analysis of P/F ratio and OI. The cooled patients (5/8 vs 12/58) were more likely to receive prone positioning than the 58 controls (12/58) or the matched controls (3/16), but mortality, VFDs, ICU-FDs, day 3 P/F ratio, and day 3 OI were similar in controls who were proned and those who were not proned (Table 4) .
Serum Mediators Before and During Hypothermia
Serum levels of IL-6, IL-10, and TGF-β were analyzed. There was no clear temporal relationship between cytokine expression and cooling (Table S2 , Supplemental Digital Content 4, http://links.lww.com/CCM/C433). Samples from the historical controls were not available for analysis of mediators.
DISCUSSION
We confirmed that cisatracurium alone does not cause hypothermia in our historical controls whose median of the average body temperatures was 36.7°C (36-37.3°C) and incidence of fever was 52% during NMB. We then showed in an open-label pilot study that surface cooling was effective and well tolerated without SAEs. Target temperature was reached within 4 (2.25-9) hours of cooling device placement, maintained below 36°C for 92% of the intended cooling period using either cooling blankets or the Arctic Sun system, and significantly different from historical controls. These results demonstrate the feasibility of studying hypothermia in patients receiving NMB for moderate to severe ARDS.
The 53.4% hospital mortality and 0 (0-12) VFDs in the controls were substantially worse than previously reported (13, 14) and reflect the extensive comorbidities in our patient population. The prospectively cooled patients also had many comorbidities (Table 1) , which contributed to the bimodal VFD and ICU-FD data. Nonetheless, the prospectively cooled patients had better outcomes compared with matched controls, including more VFDs and ICU-FDs and improved postcooling oxygenation on day 3. Several factors in this small study may have contributed to the improved outcome in the cooled patients compared with historical controls. The omission of day 3 oxygenation values from patient number 5 who died before day 3 might have changed the group results for the remaining patients, but a similar proportion of the controls (8/58) also died prior to day 3. Since our retrospective analysis period began after publication of the ARDS et Curarisation Systematique (ACURASYS) trial (13) but before the Proning Severe ARDS Patients (PROSEVA) trial (14) , only 12 of 58 controls were proned compared with five of eight cooled patients. In the PROSEVA trial, proned patients had lower 28-day and 90-day mortality (16.0% and 23.6%) and more VFDs (14) than our controls. The overall hospital mortality of our 58 controls, 53.4%, was higher than either the ACURASYS or PROSEVA trials. There were no large differences in outcomes between our controls who were proned and those who were not proned. The cooled patients had better day 3 P/F ratios and tended to have better OIs than the proned controls, and both deaths in the cooled patients occurred despite proning. These data suggest that differences in outcome between the cooled patients and historical controls cannot be fully explained by differences in proportion of patients proned.
ARDS was caused by pneumonia in all eight cooled patients but only 20 of 58 controls; nonpulmonary sepsis was associated with modestly higher mortality than pneumonia in the controls (50% vs 60%). The male-to-female ratio was higher in cooled patients, but ARDS-related mortality is usually higher in men (40) . Influenza may be a self-limited cause of ARDS and half of the cooled patients had influenza contribute to their acute illness; whereas, the number of historical controls with influenza is uncertain since influenza testing was not uniformly performed. Taken with the caveat that there were some important differences between the cooled patients and historical controls, these results provide encouragement to proceed with an RCT of hypothermia for ARDS. Importantly, our small prospective trial of hypothermia to 34-36°C in ARDS patients receiving NMB did not find any of the serious adverse effects previously associated with hypothermia (38) and suggest the possibility of benefit. The current study provided important information that can inform the planning of a phase IIb RCT of hypothermia for ARDS. Patients with comorbidities that worsen prognosis for survival (e.g., newly diagnosed hematologic malignancy) or liberating from mechanical ventilation (e.g., cardiomyopathy) independent of ARDS should be excluded (2); if patients receiving CRRT are included, there should be a protocolized provision for maintaining normothermia for those in the control group (3); serum potassium levels should be monitored during the cooling period. Ventilator-free days 9 (0-21. 
